Withdrawal of FDA approval for cancer medicine-Umbralisib due to unfavorable benefit-risk profile: USFDA Drug safety communication

Drug Withdrawal, Global Safety Alerts, Safety Communications, USFDA-United States of America, ,

In continuation to the recent drug safety communication for umbralisib in Feb-2022, USFDA further released a drug safety communication pertaining to the withdrawal of approval for umbralisib. Ukoniq (umbralisib) is a cancer medicine used in the treatment of below two specific types of lymphomas. It is a PI3 kinase inhibitor, which controls the multiplication and…

Read More

Umbralisib and potential increased risk of death [under USFDA investigation]: Need for consistent evaluation of benefits & risks

Drug Safety Alert, Global Safety Alerts, Medicinal Product Updates, Safety Communications, US-FDA, USFDA-United States of America,

USFDA released a drug safety communication for the updated significant safety information of the cancer medicine – umbralisib to disseminate awareness for optimal, safe & effective usage of this product in patients suffering from cancer of the lymph nodes and respective healthcare professionals involved in treating this patients. Ukoniq (umbralisib) is a cancer medicine used…

Read More

error: Content is protected !!